<p>市场表现出令人印象深刻的增长，过去一周增长了 4.2%，过去一年增长了 29%，而收益预计每年增长 16%。尽管 “便士股票” 这个术语可能显得过时，但它仍然代表着一个投资领域，可以在较小或较新的公司中发现重大机会。通过关注那些财务状况良好且具有明确增长潜力的公司，投资者可以在优质便士股票中找到隐藏的价值，这些股票既提供稳定性又有上升空间。</p>
<h3>美国十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3711</td>
<td>$67.77M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.29</td>
<td>$371.86M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.98</td>
<td>$1.25B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.73</td>
<td>$82.89M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$187.84M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.61</td>
<td>$361.11M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.17</td>
<td>$53.14M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$312.37M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.875</td>
<td>$6.5M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股票筛选器的 355 只股票的完整列表。</p>
<p>以下是筛选器中的一些选择。</p>
<h2>Oramed Pharmaceuticals (ORMP)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Oramed Pharmaceuticals Inc. 专注于利用技术平台进行治疗性蛋白质的口服递送的制药解决方案的研究与开发，市值约为 1.4278 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自与其专有产品和技术相关的研究与开发活动，总计 200 万美元。</p>
<p><strong>市值：</strong> $142.78M</p>
<p>Oramed Pharmaceuticals 已转向盈利，2025 年报告净收入为 6405 万美元，而前一年则出现亏损。尽管收入仅为 200 万美元，但其强大的财务状况体现在没有债务和短期资产显著超过负债。管理层和董事会经验丰富，平均任期超过七年。公司完成了一项股票回购计划，回购了近 4.77% 的股份，耗资 463 万美元，表明对其在低市盈率 2.4 倍下的估值充满信心，而整体市场的市盈率为 19.2 倍。</p>
<ul>
<li>通过阅读我们的资产负债表健康报告，深入了解 Oramed Pharmaceuticals 的表现。</li>
<li>通过检查我们的业绩历史报告，了解 Oramed Pharmaceuticals 的过往记录。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis"/></p>
<p>ORMP 财务状况分析截至 2026 年 4 月</p>
<h2>Cerus (CERS)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Cerus Corporation 是一家生物医学产品公司，市值为 3.632 亿美元。</p>
<p><strong>运营：</strong> 该公司的收入主要来自其血液安全部门，报告收入为 2.0613 亿美元。</p>
<p><strong>市值：</strong> $363.2M</p>
<p>Cerus Corporation，市值为 3.632 亿美元，正通过专注于收入增长和运营稳定性来应对其亏损状态。该公司报告其血液安全部门的收入为 2.0613 亿美元，并预测 2026 年将进一步增长至 2.24 亿至 2.28 亿美元。尽管 Cerus 的亏损在五年内每年减少了 25.6%，但由于正现金流增长 33.8%，其稳定的现金流超过三年。最近的领导层变动可能会影响战略方向，Vivek Jayaraman 将于 2026 年 7 月接任首席执行官，接替任职多年的首席执行官 William Greenman。</p>
<ul>
<li>点击这里发现 Cerus 的细微差别，查看我们的详细分析财务健康报告。</li>
<li>检查 Cerus 的收益增长报告，以了解分析师对其表现的预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/015d1c21-41dd-4ebf-ac7b-4f569b482235/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/015d1c21-41dd-4ebf-ac7b-4f569b482235/chart/financial-position-analysis"/></p>
<p>CERS 财务状况分析截至 2026 年 4 月</p>
<h2>LifeMD (LFMD)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> LifeMD, Inc. 是一家直接面向患者的远程医疗公司，在美国提供虚拟医疗护理和药房服务，市值为 1.6647 亿美元。</p>
<p><strong>运营：</strong> 该公司的收入来自其远程医疗部门，金额为 1.9406 亿美元。</p>
<p><strong>市值：</strong> $166.47M</p>
<p>LifeMD, Inc.，市值为 1.6647 亿美元，尽管尚未盈利，但正在推进其远程医疗服务。该公司在其远程医疗部门显示出显著的收入增长，报告收入为 1.9406 亿美元，并预测 2026 年将达到 2.2 亿至 2.3 亿美元。最近的举措包括通过与 LillyDirect 的整合提供新获得 FDA 批准的体重管理药物 Foundayo，增强 LifeMD 在体重管理护理方面的服务。公司保持稳定的现金流超过三年，并且没有债务，为其在执行团队内持续的战略领导变动提供了财务灵活性。</p>
<ul>
<li>点击探索我们在 LifeMD 财务健康报告中的详细发现。</li>
<li>查看我们的增长表现报告，以获取 LifeMD 未来的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/feefdf8c-475e-4a0b-9631-aa0d54962629/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/feefdf8c-475e-4a0b-9631-aa0d54962629/chart/financial-position-analysis"/></p>
<p>LFMD 财务状况分析截至 2026 年 4 月</p>
<h2>抓住机会</h2>
<ul>
<li>在这里开始您的投资之旅，了解我们精选的 355 只美国便士股票。</li>
<li>准备好尝试不同的方法了吗？通过稳健的分红股票来多样化您的投资组合，以应对潜在的市场波动。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> AI 股票筛选器与警报</h3>
<p>我们的新 AI 股票筛选器每天扫描市场，发现机会。</p>
<p>• 分红强劲的股票（收益率 3% 以上）</p>
<p>• 内部人士买入的被低估小盘股</p>
<p>• 高增长的科技和 AI 公司</p>
<p>或从 50 多个指标中构建您自己的筛选器。</p>
<p>立即免费探索</p>

Oramed制药

LFMD

CERS

美国医疗保健供应商 ETF - iShares

医疗业 ETF - SPDR

标普医疗保健服务 ETF - SPDR

医疗业 ETF - Vanguard

<p>市场在过去一周上涨了 4.2%，在过去一年中上涨了 29%，预计年收益将增长 16%。Oramed Pharmaceuticals 的市值为 1.4278 亿美元，已实现盈利，预计 2025 年的净收入为 6405 万美元。Cerus Corporation 的估值为 3.632 亿美元，专注于其血液安全部门的收入增长，而 LifeMD 的市值为 1.6647 亿美元，尽管尚未盈利，但正在推进其远程医疗服务。投资者被鼓励探索低价股的机会</p>

<p>The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock' may seem outdated, it still represents an area of investment that can uncover significant opportunities in smaller or newer companies. By focusing on those with strong financials and clear growth potential, investors can find hidden value in quality penny stocks that offer both stability and upside.</p>
<div class="lb-trans"><p>市场表现出令人印象深刻的增长，过去一周增长了 4.2%，过去一年增长了 29%，而收益预计每年增长 16%。尽管 “便士股票” 这个术语可能显得过时，但它仍然代表着一个投资领域，可以在较小或较新的公司中发现重大机会。通过关注那些财务状况良好且具有明确增长潜力的公司，投资者可以在优质便士股票中找到隐藏的价值，这些股票既提供稳定性又有上升空间。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3711</td>
<td>$67.77M</td>
<td>✅ 3 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.29</td>
<td>$371.86M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.98</td>
<td>$1.25B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.73</td>
<td>$82.89M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$187.84M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.61</td>
<td>$361.11M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.17</td>
<td>$53.14M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$312.37M</td>
<td>✅ 2 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.875</td>
<td>$6.5M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3711</td>
<td>$67.77M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.29</td>
<td>$371.86M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.98</td>
<td>$1.25B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.73</td>
<td>$82.89M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$187.84M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.61</td>
<td>$361.11M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.17</td>
<td>$53.14M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$312.37M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.875</td>
<td>$6.5M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 355 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股票筛选器的 355 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是筛选器中的一些选择。</p>
</div><h2>Oramed Pharmaceuticals (ORMP)</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals (ORMP)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions utilizing a technology platform for the oral delivery of therapeutic proteins, with a market cap of approximately $142.78 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Oramed Pharmaceuticals Inc. 专注于利用技术平台进行治疗性蛋白质的口服递送的制药解决方案的研究与开发，市值约为 1.4278 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from research and development activities related to its proprietary products and technologies, totaling $2 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自与其专有产品和技术相关的研究与开发活动，总计 200 万美元。</p>
</div><p><strong>Market Cap:</strong> $142.78M</p>
<div class="lb-trans"><p><strong>市值：</strong> $142.78M</p>
</div><p>Oramed Pharmaceuticals has transitioned to profitability, reporting a net income of US$64.05 million for 2025 compared to a loss the previous year. Despite limited revenue of US$2 million, its strong financial position is underscored by no debt and significant short-term assets exceeding liabilities. The management and board are experienced, with an average tenure of over seven years. The company completed a share buyback program, repurchasing nearly 4.77% of shares for US$4.63 million, indicating confidence in its valuation at a low price-to-earnings ratio of 2.4x compared to the broader market's 19.2x.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals 已转向盈利，2025 年报告净收入为 6405 万美元，而前一年则出现亏损。尽管收入仅为 200 万美元，但其强大的财务状况体现在没有债务和短期资产显著超过负债。管理层和董事会经验丰富，平均任期超过七年。公司完成了一项股票回购计划，回购了近 4.77% 的股份，耗资 463 万美元，表明对其在低市盈率 2.4 倍下的估值充满信心，而整体市场的市盈率为 19.2 倍。</p>
</div><ul>
<li>Get an in-depth perspective on Oramed Pharmaceuticals' performance by reading our balance sheet health report here.</li>
<li>Understand Oramed Pharmaceuticals' track record by examining our performance history report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的资产负债表健康报告，深入了解 Oramed Pharmaceuticals 的表现。</li>
<li>通过检查我们的业绩历史报告，了解 Oramed Pharmaceuticals 的过往记录。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis"/></p>
<p>ORMP Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>ORMP 财务状况分析截至 2026 年 4 月</p>
</div><h2>Cerus (CERS)</h2>
<div class="lb-trans"><h2>Cerus (CERS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Cerus Corporation is a biomedical products company with a market cap of $363.20 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cerus Corporation 是一家生物医学产品公司，市值为 3.632 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Blood Safety segment, which reported $206.13 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自其血液安全部门，报告收入为 2.0613 亿美元。</p>
</div><p><strong>Market Cap:</strong> $363.2M</p>
<div class="lb-trans"><p><strong>市值：</strong> $363.2M</p>
</div><p>Cerus Corporation, with a market cap of US$363.20 million, is navigating its unprofitable status by focusing on revenue growth and operational stability. The company reported US$206.13 million in revenue from its Blood Safety segment and forecasts further growth to US$224-228 million for 2026. While Cerus has seen losses decrease by 25.6% annually over five years, it maintains a stable cash runway exceeding three years due to positive free cash flow growth of 33.8%. Recent leadership changes may influence strategic direction as Vivek Jayaraman steps into the CEO role in July 2026, succeeding long-serving CEO William Greenman.</p>
<div class="lb-trans"><p>Cerus Corporation，市值为 3.632 亿美元，正通过专注于收入增长和运营稳定性来应对其亏损状态。该公司报告其血液安全部门的收入为 2.0613 亿美元，并预测 2026 年将进一步增长至 2.24 亿至 2.28 亿美元。尽管 Cerus 的亏损在五年内每年减少了 25.6%，但由于正现金流增长 33.8%，其稳定的现金流超过三年。最近的领导层变动可能会影响战略方向，Vivek Jayaraman 将于 2026 年 7 月接任首席执行官，接替任职多年的首席执行官 William Greenman。</p>
</div><ul>
<li>Click here to discover the nuances of Cerus with our detailed analytical financial health report.</li>
<li>Examine Cerus' earnings growth report to understand how analysts expect it to perform.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里发现 Cerus 的细微差别，查看我们的详细分析财务健康报告。</li>
<li>检查 Cerus 的收益增长报告，以了解分析师对其表现的预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/015d1c21-41dd-4ebf-ac7b-4f569b482235/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/015d1c21-41dd-4ebf-ac7b-4f569b482235/chart/financial-position-analysis"/></p>
<p>CERS Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>CERS 财务状况分析截至 2026 年 4 月</p>
</div><h2>LifeMD (LFMD)</h2>
<div class="lb-trans"><h2>LifeMD (LFMD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> LifeMD, Inc. is a direct-to-patient telehealth company providing virtual medical care and pharmacy services in the United States, with a market cap of $166.47 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> LifeMD, Inc. 是一家直接面向患者的远程医疗公司，在美国提供虚拟医疗护理和药房服务，市值为 1.6647 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its telehealth segment, which amounts to $194.06 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入来自其远程医疗部门，金额为 1.9406 亿美元。</p>
</div><p><strong>Market Cap:</strong> $166.47M</p>
<div class="lb-trans"><p><strong>市值：</strong> $166.47M</p>
</div><p>LifeMD, Inc., with a market cap of US$166.47 million, is advancing its telehealth services despite being unprofitable. The company has shown significant revenue growth from its telehealth segment, reporting US$194.06 million in revenue and forecasting between US$220 million to US$230 million for 2026. Recent initiatives include offering the newly FDA-approved weight management drug Foundayo through an integration with LillyDirect, enhancing LifeMD's service offerings in weight management care. The company maintains a stable cash runway exceeding three years and remains debt-free, providing financial flexibility amidst ongoing strategic leadership changes within its executive team.</p>
<div class="lb-trans"><p>LifeMD, Inc.，市值为 1.6647 亿美元，尽管尚未盈利，但正在推进其远程医疗服务。该公司在其远程医疗部门显示出显著的收入增长，报告收入为 1.9406 亿美元，并预测 2026 年将达到 2.2 亿至 2.3 亿美元。最近的举措包括通过与 LillyDirect 的整合提供新获得 FDA 批准的体重管理药物 Foundayo，增强 LifeMD 在体重管理护理方面的服务。公司保持稳定的现金流超过三年，并且没有债务，为其在执行团队内持续的战略领导变动提供了财务灵活性。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in LifeMD's financial health report.</li>
<li>Review our growth performance report to gain insights into LifeMD's future.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 LifeMD 财务健康报告中的详细发现。</li>
<li>查看我们的增长表现报告，以获取 LifeMD 未来的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/feefdf8c-475e-4a0b-9631-aa0d54962629/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/feefdf8c-475e-4a0b-9631-aa0d54962629/chart/financial-position-analysis"/></p>
<p>LFMD Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>LFMD 财务状况分析截至 2026 年 4 月</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Embark on your investment journey to our 355 US Penny Stocks selection here.</li>
<li>Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里开始您的投资之旅，了解我们精选的 355 只美国便士股票。</li>
<li>准备好尝试不同的方法了吗？通过稳健的分红股票来多样化您的投资组合，以应对潜在的市场波动。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> AI 股票筛选器与警报</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场，发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲的股票（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士买入的被低估小盘股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或从 50 多个指标中构建您自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

Oramed 制药和另外两个有前景的便士股适合精明的投资者